Enhanc3D Genomics has appointed Dr Hazel Jones, a former executive at AstraZeneca, as its permanent CEO. Dr Jones, who has been acting as the company’s interim CEO and COO for the past six months, has been instrumental in overseeing the company’s global operations and executing its strategic vision. Her previous roles at AstraZeneca included executive product director of clinical data and head of business planning and operations in oncology R&D. Enhanc3D Genomics has developed an innovative genome-wide 3D-genome mapping technology named GenLink3D, which offers significant insights into gene regulation and disease pathways. The company aims to leverage this technology for both commercial and academic partnerships to facilitate drug discovery and patient stratification. Dr Jones expressed her excitement about leading the company during this critical phase of transitioning to full commercialisation.

Biotechnology, Healthcare, Pharmaceuticals,United Kingdom

Former AstraZeneca figure named CEO at Cambridge MedTech